ReviewInternational journal of hematology2013
Gene mutations of acute myeloid leukemia in the genome era.
Review in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 63 citations in OpenAlex.
- Review
- Advancements in genetic analysis: Insights from a case study and review of next-generation sequencing techniques for veterinary oncology applications.Veterinary clinical pathology · 2025Review
- Review
- Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML.NPJ precision oncology · 2025Article
- Identification of a novel mutation of the FLT3 gene located on the juxtamembrane domain from acute myeloid leukemia patients.Molecular biology reports · 2024Article
- Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.Saudi journal of biological sciences · 2021Article
- Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.Human cell · 2020Article
- ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.Nagoya journal of medical science · 2020Review
- A structured population model of clonal selection in acute leukemias with multiple maturation stages.Journal of mathematical biology · 2019Article
- Novel therapeutic strategy based on genetic and epigenetic abnormalities for myeloid neoplasms.International journal of clinical oncology · 2019Review
- Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.International journal of clinical oncology · 2019Review
- Enigmatic Ladies of the Rings: How Cohesin Dysfunction Affects Myeloid Neoplasms Insurgence.Frontiers in cell and developmental biology · 2019Article
- Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.Cancer gene therapy · 2018Article
- Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.Leukemia research · 2018Article
- Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.Genes, chromosomes & cancer · 2017Article
- Flexible model-based clustering of mixed binary and continuous data: application to genetic regulation and cancer.Nucleic acids research · 2017Article
- Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.Leukemia research · 2016Article
- Emergence of heterogeneity in acute leukemias.Biology direct · 2016Article
- Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.Cancer science · 2016Article
- Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ten years ago, gene mutations found in acute myeloid leukemia (AML) were conceptually grouped into class I mutation, which causes constitutive activation of intracellular signals that contribute to the growth and survival, and class II mutation, which blocks differentiation and/or enhance self-renewal by altered transcription factors. A cooperative model between two classes of mutations has been suggested by murine experiments and partly supported by epidemiological findings. In the last 5 years, comprehensive genomic analysis proceeded to find new gene mutations, which are found in the epigenome-associated enzymes and the molecules never noticed so far. These new mutations apparently increase the complexity and heterogeneity of AML. Although a long list of gene mutations might have been compiled, the entire picture of molecular pathogenesis in AML remains to be elucidated because gene rearrangement, gene copy number, DNA methylation and expression profiles are not fully studied in conjunction with gene mutations. Comprehensive genome research will deepen the understanding of AML to promote the development of new classification and treatment. This review focuses on gene mutations that were recently discovered by genome sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.